Your prediction
DBV Technologies S.A. ADR Stock
Pros and Cons of DBV Technologies S.A. ADR in the next few years
Pros
Cons
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.The financials of DBV Technologies, a company in the pharmaceutical industry, provide a mixed impression. On one hand, the company shows potential for growth, backed by a significant increase in total assets between 2020 and 2022. However, it is impossible to overlook the consistently negative net income throughout the reported period.
Increase in Total Assets: DBV Technologies has experienced a substantial increase in its total assets, from $146.7 million in 2021 to $246.5 million in 2022. This growth suggests the company's capability to accumulate and manage resources for potential expansion and business ventures.
Decrease in Total Liabilities: The company has shown a decline in total liabilities, decreasing from $66.8 million in 2020 to $52 million in 2022, indicating a better financial position and ability to manage obligations.